Parkinson’s Disease · FGF-1 Research Studies
Parkinson’s takes things slowly — a voice, a signature, a walk in the park, a person. Since May 2022, the people in our research studies have written to tell us what they are getting back.
Read their wordsEvery story here began with a diagnosis.
Zhittya believes that FGF-1 works by growing new blood vessels in the brain — restoring flow where Parkinson’s has taken it away.
These are the people living that science, in their own words.
Research underway since May 2022. Patient commentary on this page compiled from monthly updates beginning January 2023.
More journeys
Every voice
Browse all 103 Parkinson’s comments by what changed for them. Choose a topic — balance, tremor, speech, sleep, and more.
No comments match this topic yet.
The science, briefly
FGF-1 is a naturally occurring protein that drives angiogenesis — the growth of new blood vessels — and can support neurogenesis, the growth of new neurons. A lack of blood flow to dopamine-producing regions of the brain is believed to be a root cause of Parkinson’s symptoms. By reestablishing that flow, Zhittya’s research aims to reach the cause, not just the symptoms.
These are individual experiences shared during ongoing medical research studies and are not a guarantee of results. FGF-1 is investigational. For details on the science and how to participate, visit zgm.care/parkinsons.
Explore the research
